[
  {
    "ts": null,
    "headline": "The 5 Most Interesting Analyst Questions From Bio-Techne’s Q2 Earnings Call",
    "summary": "Bio-Techne’s second quarter results were met with a negative market reaction despite topping Wall Street’s revenue and profit expectations. Management attributed the performance to robust growth from large pharmaceutical customers, driven by continued demand for automated proteomic analytical instruments and cell therapy solutions. However, the company faced margin compression, which President and CEO Kim Kelderman linked to unfavorable product mix and ongoing challenges in the biotech and acade",
    "url": "https://finnhub.io/api/news?id=8cb39e058cc31540a3fa6ee21244b90698ce9382ebc4f6a503c2345c97783277",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755063341,
      "headline": "The 5 Most Interesting Analyst Questions From Bio-Techne’s Q2 Earnings Call",
      "id": 136328954,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Bio-Techne’s second quarter results were met with a negative market reaction despite topping Wall Street’s revenue and profit expectations. Management attributed the performance to robust growth from large pharmaceutical customers, driven by continued demand for automated proteomic analytical instruments and cell therapy solutions. However, the company faced margin compression, which President and CEO Kim Kelderman linked to unfavorable product mix and ongoing challenges in the biotech and acade",
      "url": "https://finnhub.io/api/news?id=8cb39e058cc31540a3fa6ee21244b90698ce9382ebc4f6a503c2345c97783277"
    }
  }
]